Pricing Log in Create free account
Saturday 17 October 2026 Export RVP’s income statement to Excel — free account

Retractable Technologies, Inc.

RVP Healthcare Medical Instruments & Supplies

Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 31.1%, EPS was flat, free cash flow grew 56.7% and total debt fell 32.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.58 0.01 −1.69%
Market cap
$17.6M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
0.57
Beneish M
−15.44
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 3 — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 59.21%

Capital & Financial Ratios $m

Market Cap 17.61
Revenue 33.90
Net Income (3.37)
Free Cash Flow (5.11)
Net Debt (39.15)
Current Ratio 4.93 (at or above 1.5: strong)
Debt/Equity 0.01 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 11.10
P/S ratio 0.51
P/B ratio 0.24
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (49.68%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.6×, against a ten-year median of 0.4×; over the ten years it ranged from −0.7× in 2024 to 8.1× in 2020.
P/S against its own 10 years 3.80%
10-year low 10-year high
P/B against its own 10 years 1.14%
10-year low 10-year high
EV/FCF against its own 10 years 66.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 47 45 37 40
Receivables 12 9 8 9
Inventory 18 19 17 16
Other 1 1 1 1
78 73 63 66
2023 2024 2025 Q'26
Payables 5 4 5 7
ST’ Debt 0 0 0 0
Other — — — —
9 9 10 13

Compound Annual Growth %

10y 5y 3y
Sales 2.62% (14.11%) (26.10%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.22% 8.32% (11.29%)

Revenue $m

Mar Jun Sep Dec Year
’26 7 7 — — —
’25 8 10 10 9 38
’24 8 6 10 9 33
’23 11 8 10 14 44
’22 45 14 23 13 95
’21 50 42 36 59 188
’20 11 12 27 32 82
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 (1) (4) (1) (1) (7)
’24 (2) (3) (6) (1) (12)
’23 (4) (3) 8 2 3
’22 21 (8) (8) 12 17
’21 17 15 (13) 15 33
’20 2 (2) 9 10 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 (2) (4) (1) (1) (8)
’24 (2) (3) (7) (1) (13)
’23 (4) (3) 8 2 2
’22 16 (14) (12) 9 0
’21 4 (11) (22) 3 (26)
’20 2 (2) 0 (1) (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.14) 0.09 — — —
’25 (0.35) 0.00 0.01 (0.08) (0.43)
’24 0.01 (0.48) (0.07) 0.13 (0.40)
’23 0.03 (0.13) (0.14) 0.00 (0.24)
’22 0.22 (0.11) 0.16 (0.13) 0.15
’21 0.52 0.31 0.19 0.61 1.63
’20 0.00 0.11 0.25 0.35 0.80
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 0.88 0.54 0.54 0.56 0.97 6.57 1.61 0.95 0.56 0.62

Analyst estimates 2026–2028

Powerpack
High 3.15 1.48 1.08 1.60 15.79 21.50 7.37 2.11 1.34 1.14
People
People Employees 135 150 125 140 182 235 198 151 227 201
Revenue/emp, $m 0.22 0.23 0.27 0.30 0.45 0.80 0.48 0.29 0.15 0.19
Income, $m
Income, $m Revenue 30 34 33 42 82 188 95 44 33 38
Gross margin, % 34.67 28.91 30.72 33.83 45.21 50.62 29.80 20.89 (3.11) 0.12
EBT (4) (4) (1) 3 26 75 5 (9) (4) (12)
EBT margin, % (12.38) (11.37) (4.07) 7.55 31.85 39.79 5.44 (20.45) (10.65) (32.08)
Net income (4) (4) (1) 3 24 56 5 (7) (12) (13)
Depreciation 1 1 1 1 1 1 5 8 8 8
Per share, $
Per share, $ Revenue 1.02 1.08 1.02 1.28 2.47 5.56 2.88 1.46 1.10 1.28
Earnings (0.15) (0.14) (0.06) 0.07 0.80 1.65 0.15 (0.24) (0.40) (0.43)
Cash flow (0.03) (0.09) (0.04) 0.07 0.57 0.97 0.51 0.09 (0.39) (0.24)
Capex (0.07) 0.00 (0.01) (0.02) (0.63) (1.72) (0.51) (0.03) (0.05) (0.02)
Free cash flow (0.09) (0.09) (0.05) 0.05 (0.06) (0.75) 0.00 0.06 (0.43) (0.25)
Book value 0.96 0.85 0.78 0.87 1.50 2.93 3.24 3.32 2.91 2.48
Shares, m 29 32 33 33 33 34 33 30 30 30
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 18.75 14.95 4.20 11.47 0.00 0.00 0.00
P/S 0.95 0.63 0.59 1.17 4.35 1.25 0.60 0.74 0.63 0.60
P/B 1.04 0.82 0.79 1.76 7.18 2.37 0.53 0.33 0.24 0.31
EV/Sales 0.54 0.30 0.30 0.91 3.94 1.00 0.07 (0.31) (0.69) (0.34)
EV/FCF (5.91) (3.43) (6.35) 24.28 (157.13) (7.37) (112.85) (7.01) 1.74 1.71
Cash, $m
Cash, $m Operating cash flow (1) (3) (1) 2 19 33 17 3 (12) (7)
Capex (2) 0 0 (1) (21) (58) (17) (1) (1) (1)
Free cash flow (3) (3) (2) 2 (2) (26) 0 2 (13) (8)
Balance, $m
Balance, $m Working capital 20 19 17 20 42 69 77 68 64 53
Total debt 4 3 3 3 4 2 2 2 1 1
Net debt (12) (11) (10) (11) (34) (46) (50) (46) (43) (36)
Shareholders’ equity 28 27 26 29 50 99 107 99 87 74
Returns, %
Returns, % ROA (10.85) (11.54) (5.45) 6.42 36.94 35.87 2.41 (3.86) (7.12) (8.44)
ROIC (13.84) (14.96) (5.18) 10.63 92.90 85.74 (0.94) (13.41) (30.09) (34.56)
ROE (15.35) (16.53) (7.98) 9.30 68.81 75.15 4.72 (7.05) (13.03) (15.89)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Retractable Technologies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEPH Nephros Inc. $38.1M 23.4× 76.0× +36.16% (above 0%: growing) +450.00% (above 0%: growing) −31.49% (below 0%: shrinking) 66.91% 20.16% Compare
HBIO Harvard Bioscience, Inc. $37.8M — (loss-making) — (loss-making) +11.13% (above 0%: growing) n/m −123.43% (below 0%: shrinking) 55.57% (4.30%) Compare
MLSS Milestone Scientific, Inc. $29.6M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
RVP Retractable Technologies, Inc. $17.6M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%)
BNGO Bionano Genomics, Inc. $16.1M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $15.9M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%) Compare
FEMY Femasys Inc. $14.5M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%) Compare
CUPR Cuprina Holdings (Cayman) Limited $11.5M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $10.9M — — — — −132.79% (below 0%: shrinking) — — Compare
Median of peers $16.0M — — +21.82% — −33.93% 56.33% (52.66%)

All 55 Medical Instruments & Supplies stocks →

Retractable Technologies, Inc. (RVP) key facts

  • Strength: Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024.
  • Retractable Technologies, Inc. (RVP) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, RVP traded at $0.58, a market capitalization of $17.6 million.
  • Return on equity was −15.9% and debt-to-equity 0.01.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.57 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Retractable Technologies, Inc. (RVP) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RVP · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com